1. No category

ALZHEIMER’S DISEASE:
THE LATEST SCIENTIFIC RESEARCH & INNOVATION
Alzheimer’s disease is a condition without a
cure; it affects 35 million people worldwide and
care costs in the United States alone are on
course to reach $1.1 trillion by 2050. To date, no
drug has reached the market that is able to
slow its progress – currently approved agents
treat only its symptoms. Despite the desperate
need for a breakthrough, the area has been
somewhat marginalized with funding in very
short supply. Expectations have been further
dampened by the recent failures of several
late-stage and previously promising agents.
However, a number of recent advances have
cast a more hopeful light on this potentially
lucrative field. The U.S. Government has
pledged $130 million for R&D into the disease,
with a further $26 million for ancillary issues
such as care-giver support. New diagnostic
agents are entering the market that will help
identify and treat patients, and a number of
studies investigating the very early stages of
the disease have been launched.
“ We really owe it to ourselves and
future generations to create a world
without Alzheimer’s, and I think we can.
Twenty years ago I wouldn’t have said
that—we didn’t know enough. And now
it’s changed so dramatically that I say a
cure will come as quickly as the people
want it to come, in terms of being willing
to commit the necessary resources.”
John Q. Trojanowski, MD, PhD
This infographic showcases Alzheimer’s research and innovation activity based on data from
Thomson Reuters Derwent World Patents Index® (DWPI SM ) and Web of Science .TM It gives a
glimpse into how much time, effort and money are being dedicated to the disease and who
the key players are.
Alzheimer’s Research
Number of Alzheimer's Research Papers
Center for Neurodegenerative Disease Research
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA USA
2010-2014
Source: Thomson Reuters Web of Science
13,000
“ A home run in my mind for an Alzheimer’s
12,500
drug would be something that delays the
12,000
onset that far fewer people would develop
the disease during their lifetime. If we had
11,500
a drug today that would do that, by 2050
the incidence and prevalence would be half
11,000
of what it would otherwise be — and so
would the $3 trillion price tag of caring for
10,500
those affected.”
10,000
9,500
10,456
10,865
11,886
12,431
12,065
2010
2011
2012
2013
2014
John Q. Trojanowski, MD, PhD
Center for Neurodegenerative Disease Research
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA USA
9,000
Alzheimer’s Innovation
2010-2014
Alzheimer ’s Drug Inventions
Source: Thomson Reuters Derwent World Patents Index
Patent Count
900
800
700
600
500
400
300
200
805
722
669
649
684
2010
2011
2012
2013
2014
100
0
Top 20 Companies
Alzheimer ’s Drug Inventions
2010-2014
Source: Thomson Reuters Derwent World Patents Index
Hoffmann La Roche
Bayer Pharmaceuticals
Merck Sharp & Dohme
Boehringer Ingelheim Int.
Janssen Pharmaceuticals
Abbvie
Novartis
Bristol-Myers Squibb
University California
Glaxosmithkline
University Nat Tsing-Hua
Gp Medical
Genentech
Eisai R&D Management
Shionogi & Company
Korea Inst. Science & Tech
Astrazeneca
University Kyung Hee
Takeda Pharmaceuticals
Arqule
0
Top 10 Countries
Alzheimer ’s Drug Inventions
10
20
30
40
50
60
70
80
2010-2014
Source: Thomson Reuters Derwent World Patents Index
2010-2014
3363
Inventions
1644
417
349
314
309
102
87
71
42
28
US
CN
JP
KR
EP
WO
GB
IN
DE
FR
http://sciencewatch.com